Vivimed Labs Ltd
Vivimed Labs Ltd (VIVIMEDLAB) last reported results for the quarter ended Mar 2026, with sales of ₹12 crore and net profit of ₹-147 crore. The stock last traded at ₹6.18, a market capitalisation of ₹51.2 crore. Over the past 52 weeks the stock has ranged between ₹4.75 and ₹29.4. Figures are as of 6 Oct 2026 and are not real time.
Vivimed Labs Ltd share price and key metrics
- Current price
- ₹6.18
- Market cap
- ₹51.2 cr
- Book value
- ₹-25.4
- ROE
- %
- ROCE
- -65.2%
- Dividend yield
- 0.00%
- 52w high / low
- 29.4/4.75
Metrics as of 6 Oct 2026. Not real time.
Track Vivimed Labs Ltd
Cruxal reads every Vivimed Labs Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Vivimed Labs Ltd growth and returns
- 10 Years
- -26%
- 5 Years
- -39%
- 3 Years
- -28%
- TTM
- -40%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 14%
- TTM
- -452%
- 10 Years
- -26%
- 5 Years
- -23%
- 3 Years
- 7%
- 1 Year
- %
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- Last Year
- %
Vivimed Labs Ltd quarterly results
In the quarter ended Mar 2026, sales were ₹12 cr, down 53.8% from ₹26 cr a year earlier. Net profit was ₹-147 cr, down 2350.0% year on year.
| ₹ crore | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 29 | 25 | 37 | 26 | 21 | 21 | 16 | 12 |
| Expenses | 40 | 25 | 35 | 28 | 22 | 22 | 27 | 152 |
| Operating profit | -11 | -1 | 1 | -2 | -0 | -1 | -11 | -140 |
| OPM % | -37% | -2.6% | 2.9% | -10% | -1.3% | -4.6% | -68% | -1,169% |
| Other income | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 6 |
| Interest | 0 | 0 | 0 | 2 | 1 | 2 | 1 | 1 |
| Depreciation | 4 | 4 | 7 | 6 | 5 | 5 | 5 | 12 |
| Profit before tax | -15 | -5 | -6 | -5 | -5 | -7 | -17 | -147 |
| Tax % | 0% | 0% | 0% | 2% | 0% | 0% | 0% | 0% |
| Net profit | -15 | -5 | -6 | -6 | -5 | -7 | -17 | -147 |
| EPS (₹) | -1.84 | -0.62 | -0.72 | -0.68 | -0.66 | -0.88 | -2.00 | -17.74 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Vivimed Labs Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,462 | 1,186 | 1,315 | 1,059 | 861 | 237 | 187 | 149 | 116 | 70 |
| Operating profit | 404 | 215 | 180 | 10 | 32 | -8 | -187 | -33 | -13 | -152 |
| OPM % | 28% | 18% | 14% | 1.0% | 3.7% | -3.3% | -100% | -22% | -11% | -218% |
| Net profit | 214 | 76 | 57 | -109 | -72 | -68 | -329 | -45 | -32 | -176 |
| EPS (₹) | 26.41 | 9.44 | 6.95 | -13.16 | -8.67 | -8.16 | -39.62 | -5.48 | -3.85 | -21.28 |
TTM is the trailing twelve months to the most recent quarter.
Vivimed Labs Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 16 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 |
| Reserves | 718 | 885 | 602 | 493 | 415 | 348 | 23 | -22 | -52 | -227 |
| Borrowings | 1,011 | 1,149 | 1,280 | 1,268 | 326 | 359 | 379 | 377 | 376 | 397 |
| Other liabilities | 317 | 343 | 431 | 432 | 532 | 543 | 658 | 579 | 580 | 567 |
| Total liabilities | 2,062 | 2,394 | 2,329 | 2,210 | 1,289 | 1,266 | 1,076 | 950 | 921 | 753 |
| Fixed assets | 879 | 1,035 | 965 | 1,045 | 502 | 520 | 436 | 418 | 408 | 386 |
| CWIP | 76 | 65 | 122 | 89 | 60 | 40 | 21 | 21 | 17 | 18 |
| Investments | 3 | 3 | 3 | 86 | 199 | 199 | 199 | 168 | 168 | 181 |
| Other assets | 1,104 | 1,290 | 1,239 | 990 | 529 | 507 | 421 | 343 | 328 | 170 |
| Total assets | 2,062 | 2,394 | 2,329 | 2,210 | 1,289 | 1,266 | 1,076 | 950 | 921 | 753 |
As reported by the company. Total assets equal total liabilities by construction.
Vivimed Labs Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 58 | 21 | 422 | 80 | 567 | 28 | 35 | -24 | -2 | 8 |
| Cash from investing | -68 | -164 | -89 | -196 | 404 | -16 | -5 | 28 | -5 | -1 |
| Cash from financing | 35 | 186 | -338 | 72 | -1,015 | -10 | -34 | -6 | 5 | -6 |
| Net cash flow | 25 | 44 | -5 | -44 | -44 | 1 | -3 | -2 | -1 | 1 |
| Free cash flow | -11 | -142 | 333 | -33 | 1,084 | 11 | 30 | -26 | -6 | 7 |
| CFO / operating profit | 23% | 30% | 243% | 972% | 1,720% | -352% | -19% | 73% | 13% | -5% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Vivimed Labs Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 22% | 9% | 7% | -3% | -1% | -3% | -52% | -11% | -8% | -65% |
| Debtor days | 50 | 85 | 99 | 86 | 46 | 134 | 145 | 203 | 233 | 236 |
| Inventory days | 329 | 411 | 397 | 396 | 263 | 573 | 216 | 327 | 358 | 63 |
| Days payable | 122 | 154 | 207 | 179 | 35 | 100 | 74 | 225 | 240 | 263 |
| Cash conversion cycle | 258 | 342 | 288 | 303 | 274 | 607 | 286 | 305 | 351 | 36 |
| Working capital days | 55 | 121 | 68 | 216 | 77 | 195 | -15 | -171 | -255 | -1,468 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Vivimed Labs Ltd shareholding pattern
Promoters held 7.57% at Mar 2026, down from 20.94% at Mar 2025. FIIs 1.64%.
| % held | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 20.94% | 20.94% | 20.94% | 20.94% | 7.76% | 7.76% | 7.76% | 7.57% |
| FIIs | 1.64% | 1.64% | 1.64% | 1.64% | 1.64% | 1.64% | 1.64% | 1.64% |
| Government | 0.12% | 0.12% | 0.12% | 0.12% | 0.12% | 0.12% | 0.12% | 0.12% |
| Public | 77.30% | 77.30% | 77.30% | 77.30% | 90.47% | 90.47% | 90.47% | 90.66% |
| No. of shareholders | 49,012 | 49,003 | 49,005 | 48,957 | 48,928 | 48,925 | 49,221 | 47,492 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Vivimed Labs Ltd corporate filings
- Vivimed Labs Ltd announces meeting of Committee of Creditors under CIRPCompany Updatelow impact
Cruxal's analysis: Vivimed Labs Ltd has issued an intimation regarding a meeting of the Committee of…
Read the full analysis - Vivimed Labs Limited seeks three-month extension for AGM convening for FY 2025-26Company Updatelow impact
Cruxal's analysis: Vivimed Labs Limited has announced that its Committee of Creditors has approved an…
Read the full analysis - closure of trading windowInsider Trading / SASTlow impact
- Vivimed Labs Ltd schedules Committee of Creditors meeting for 10th September 2026 under CIRPCompany Updatelow impact
Cruxal's analysis: Vivimed Labs Ltd, currently undergoing the Corporate Insolvency Resolution Process…
Read the full analysis - Vivimed Labs Ltd schedules 6th Committee of Creditors (CoC) meeting for August 18, 2026Company Updatelow impact
Cruxal's analysis: Vivimed Labs, currently undergoing Corporate Insolvency Resolution Process (CIRP), has…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.